SLDB · Solid Biosciences
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $9.04
Note written ·
Price against the kill line
24.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $9.04, on record since 11 November 2026. The shares are down 24.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $9.04, which would recover most of the slide from the July high and show the shares leading the S&P 500. FDA minutes that support an accelerated-approval filing on the 12-month SGT-003 dataset would also show the shares leading.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −200
- Free-cash-flow yield (%)
- −26.2
All filed numbers
What Solid Biosciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −215 | −53.9 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +60.0 |
| Operating cash flow ($M) | −199 |
| Capital spending ($M) | 1.4 |
| Free cash flow ($M) | −200 |
| Cash and short-term investments ($M) | 349 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 342 |
| Market value ($M) | 763 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.2 |
| Free-cash-flow yield (%) | −26.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.0% of shares outstanding sold short, 8.5 days of average trading to cover, −3.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $25K |
| 12 monthsfrom | $0 | $2.7M |
The thesis
Solid Biosciences' Duchenne muscular dystrophy gene therapy, SGT-003, is more likely to lag the S&P 500 than lead it over the next three months. The company has scheduled a Food and Drug Administration (FDA) Type C meeting for late in the fourth quarter of 2026, and the minutes from that meeting decide whether an accelerated-approval filing on a small 12-month dataset stays open.
The shares closed at $7.00 on 12 November 2026, 38.9% below the intraday 52-week high of $11.45 on 6 July 2026. The three-month change is −23.9%. The shares rose from $6.18 on 5 November 2026 to $7.60 on 11 November 2026 after the third-quarter report, then fell back to $7.00 on 12 November 2026.
The third-quarter report on 4 November 2026 said the Type C meeting will discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and seek guidance on a potential accelerated-approval path. The company said it will update investors after it receives formal minutes and gave no date for them. Management said at the Citi presentation on 10 September 2026 that minutes could be disclosed in early 2027.
The market has priced in substantial doubt: the shares sit under both their 50-day and 200-day averages while coverage keeps widening, with William Blair starting coverage at Outperform on 9 November 2026 and 10 November 2026 according to company-news headlines.
Bullish and bearish views on Solid Biosciences Inc.
The bull case on Solid Biosciences Inc. (SLDB), in brief: FDA meeting is now scheduled. The bear case: functional benefit is not yet shown to the FDA.
Bull case
- FDA meeting is now scheduled. The 4 November 2026 release says a Type C meeting is set for late in the fourth quarter of 2026 on the SGT-003 data package. A dated meeting replaces the open-ended status management described on 10 September 2026.
- Safety disclosures remain clean. SGT-003 was described as generally well tolerated in 53 participants dosed in the Phase 1/2 trial as of 3 November 2026. The randomized Phase 3 IMPACT DUCHENNE study began dosing in the second quarter of 2026.
- Cash covers the timeline. Solid reported $348.9 million of cash, cash equivalents and available-for-sale securities at 30 September 2026 and guided its runway into the first half of 2028.
- Sell-side coverage is widening. William Blair started coverage with an Outperform rating on 9 November 2026 and 10 November 2026, per company-news headlines. UBS had initiated at Buy on 15 October 2026.
- Pipeline adds options. Circio announced a research collaboration with Solid on 11 November 2026 to evaluate its CircVec generation 5 construct with Solid's POLARIS-101 capsid for genetic heart disease. The European Commission granted SGT-212 orphan designation for Friedreich's ataxia on 26 October 2026, and five participants have been dosed in its Phase 1b FALCON trial with no treatment-related serious adverse events.
Bear case
- Functional benefit is not yet shown to the FDA. Management said on 10 September 2026 that the intended regulatory dataset is slightly more than 12 participants with one year of follow-up. The FDA has not publicly agreed that this supports an accelerated-approval filing.
- Spending is rising. Third-quarter research and development expense was $43.6 million against $38.9 million a year earlier. General and administrative expense was $14.1 million against $9.2 million, and the net loss was $53.9 million, or $0.36 per share.
- Cash is falling and equity capacity is registered. Cash and securities were $377.7 million at 30 June 2026 and $348.9 million at 30 September 2026, after $15.7 million of net at-the-market proceeds in the third quarter. A $200 million common-stock prospectus plus a mixed securities registration was filed on 6 August 2026.
- The answer may arrive after the quarter. The company gave no date for meeting minutes, and management pointed to early 2027 on 10 September 2026. The three-month window can close before the FDA position is public.
- An insider sold shares. SEC Form 4 filings show Chief Medical Officer Gabriel Brooks exercised 9,750 options on 18 October 2026 and sold 4,374 shares at $5.62 on 19 October 2026 under a Rule 10b5-1 sales plan.
Price setup
The shares closed at $7.00 on 12 November 2026. That is below the 50-day average of $7.27 and the 200-day average of $7.68, both on adjusted closes. The $7.60 close of 11 November 2026 was the high of the six sessions since 5 November 2026.
The 3-month reference close was $9.20 on 14 August 2026, and the intraday 52-week high is $11.45 from 6 July 2026. The shares would have to recover most of that decline before the call that they lag could be questioned on price alone.
The 52-week closing low is $4.24 on 14 November 2025. The $5.62 insider sale price on 19 October 2026 shows the shares traded well below today's level less than a month ago.
Registered equity capacity of $200 million means the company can issue stock into strength. It sold $15.7 million net through its at-the-market program in the third quarter.
Catalysts ahead
- 16 November 2026: Chief Executive Bo Cumbo fireside chat at the Jefferies Global Healthcare Conference in London, 2:30 p.m. GMT. A public forum where management may comment on preparation for the FDA meeting and the timing of formal minutes.
- ~15 December 2026 (est.): Type C meeting with the FDA on the SGT-003 data package, scheduled for late in the fourth quarter of 2026. The meeting and the minutes that follow decide whether an accelerated-approval filing on a small 12-month dataset remains available.
- 31 December 2026: Expected first participant dosing in the SGT-501 ARTEMIS trial, a catecholaminergic polymorphic ventricular tachycardia (heart rhythm) study. Shows whether the pipeline beyond SGT-003 keeps to its stated timetable.
What would change the view
A daily close above $9.04, which would recover most of the slide from the July high and show the shares leading the S&P 500. FDA minutes that support an accelerated-approval filing on the 12-month SGT-003 dataset would also show the shares leading.
What it trades with
SLDB trades mainly on its own regulatory news. Other Duchenne gene therapy developers move on read-across when the FDA changes its stance on accelerated approval for muscle-targeted gene therapies. Small-cap biotech funding conditions affect the shares through the equity-issuance channel, since Solid has registered capacity to sell stock. The sample of price reactions around the 2026 reports is too small to state a reliable correlation with any index.
The evidence, claim by claim (8)
- Cash, cash equivalents and available-for-sale securities were $348.9 million at 30 September 2026, down from $377.7 million at 30 June 2026; runway guided into the first half of 2028; third-quarter net at-the-market proceeds were $15.7 million. Solid Biosciences third-quarter 2026 results release · as of
- Type C meeting with the FDA scheduled for late in the fourth quarter of 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and seek guidance on a potential accelerated-approval path. Solid Biosciences third-quarter 2026 results release · as of
- SGT-003 generally well tolerated in 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of 3 November 2026; Phase 3 IMPACT DUCHENNE began dosing in the second quarter. Solid Biosciences third-quarter 2026 results release · as of
- Third-quarter 2026 net loss was $53.9 million ($0.36 per share); research and development $43.6 million against $38.9 million a year earlier; general and administrative $14.1 million against $9.2 million. Solid Biosciences third-quarter 2026 results release · as of
- Chief Medical Officer Gabriel Brooks exercised 9,750 options on 18 October 2026 and sold 4,374 shares at $5.62 on 19 October 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 20 October 2026 · as of
- Circio announced a research collaboration with Solid Biosciences to evaluate its CircVec generation 5 construct with the POLARIS-101 AAV capsid for genetic heart disease. Company news, 11 November 2026 · as of
- William Blair started coverage of Solid Biosciences with an Outperform (Buy) rating. Company news headlines, 9 November 2026 and 10 November 2026 · as of
- European Commission granted orphan designation to SGT-212 for Friedreich's ataxia; five participants dosed in the Phase 1b FALCON trial with no treatment-related serious adverse events. Company news releases · as of
Sources
- TodayTuesday, November 10, 2026 · easternherald.com ·
- BioPharmaWatch
Related · shared themes
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
LRMR
Larimar Therapeutics
Larimar Therapeutics is modestly more likely than not to lead the S&P 500 over three months: it finished its nomlabofusp filing on 9…
RZLT
Rezolute
Rezolute's ersodetug rests on the tumor hyperinsulinism upLIFT study, with topline guided to mid-December 2026; the final responder rate…
AGIO
Agios Pharmaceuticals
Agios Pharmaceuticals' shares are more likely to lag the S&P 500 until the FDA rules on mitapivat in sickle cell disease by 1 February…
See also · stocks to watch